By Dr Patrick J. Vojta, Vincent P. Kazmer and Dr Larry D. Kier Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1). This article provides a current perspective on […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!